trends in
PHARMACOLOGICAL SCIENCES
including TOXICOLOGICAL SCIENCES

Subject Index

Author Index

Books Reviewed

1994

Vol 15
Issues 1–12

ISSN 0165 6147

Trends in Pharmacological Sciences

Elsevier Trends Journals
68 Hills Road
Cambridge
UK CB2 1LA
Tel +44 (0) 1223 315961
Fax +44 (0) 1223 464430

Advisory Editorial Board

E. J. Ariëns, University of Nijmegen, Nijmegen, Netherlands
P. M. Beart, Monash University, Melbourne, Australia
N. J. M. Birdall, National Institute of Medical Research, London, UK
N. G. Bowery, School of Pharmacy, London, UK
J. N. Crawley, National Institute of Mental Health, Bethseda, MD, USA
J. R. Fozard, Sandoz, Basel, Switzerland
B. Fredholm, Karolinska Institute, Stockholm, Sweden
T. Godfraind, Université Catholique de Louvain, Louvain, Belgium
J. W. Hadden, USF Medical Center, Tampa, FL, USA
J. Hughes, Parke-Davis, Cambridge, UK
M. Lazdunski, CNRS Université de Nice, Valbonne, France
P. Leff, Fisons Pharmaceuticals, Loughborough, UK
L. Limbird, Vanderbilt University, Nashville, TN, USA
J. Meldolesi, Instituto H. San Raffaele, Milan, Italy
M. Otsuka, Tokyo Medical & Dental University, Tokyo, Japan
M. M. Reidenberg, Cornell Medical Center, New York, NY, USA
R. Ruffolo, Jr, SmithKline Beecham, King of Prussia, PA, USA
H. Timmerman, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
M. Vore, University of Kentucky, KY, USA
Z. G. Wang, Institute of Basic Medical Sciences, Beijing, China

Editor **Deborah Girdlestone**

Assistant Editor **Rosie Perkins**

Editorial Administrator **Anne Ward**

© 1995 Elsevier Science Ltd

All rights reserved. No part of this publication may be translated, reproduced, stored in an electronic retrieval system, published or transmitted, in any form or by any means, such as but not limited to, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the copyright owner and the publisher, Elsevier Trends Journals, 68 Hills Road, Cambridge, UK CB2 1LA.

Author Index

BR Book Review
L Letter
SR Software Review

A

Adcock, I., *see* Barnes, P.
Albert, P. R. and Morris, S. J., Antisense knockouts: molecular scalpels for the dissection of signal transduction 250
Ali, H., *see* Beaven, M. A.
Allen, T. M., Long-circulating (sterically stabilized) liposomes for targeted drug delivery 215
Allsop, D., *see* Eikelenboom, P.
Anderson, G. P. and Coyle, A. J., T_H2 and 'T_H2-like' cells in allergy and asthma: pharmacological perspectives 324

B

Bagetta, G., Corasaniti, T. M., Finazzi-Agrò, A. and Nisticò, G., Does the HIV-1 coat protein gp120 produce brain damage? (L) 362
Barlow, R. B., *A Dictionary of Pharmacology and Clinical Drug Evaluation*, (BR) 391
Barlow, R. B., Problems associated with the partiality of a partial agonist, (L) 320
Barnard, E. A., Burnstock, G. and Webb, T. E., Barnard, Burnstock and Webb reply, (L) 280
Barnard, E. A., Burnstock, G. and Webb, T. E., G protein-coupled receptors for ATP and other nucleotides: a new receptor family 67
Barnes, P. and Adcock, I., Barnes and Adcock reply, (L) 139
Bauer, C., *see* Paolini, M.
Bax, W. A. and Saxena, P. R., The current endothelin receptor classification: time for reconsideration? 379
Beaven, M. A., Ramkumar, V. and Ali, H., Adenosine A_3 receptors in mast cells, (L) 13
Bell, C., Comments from the Australian Physiological & Pharmacological Society 176
Belz, G. G. and Kimbel, K. H., Comments from the Association of German Clinical Pharmacologists 410
Bennett, B. M., McDonald, B. J., Nigam, R. and Simon, W. C., Biotransformation of organic nitrates and vascular smooth muscle cell function 245
Beprozvanny, I., *see* Ehrlich, B. E.
Bezprozvannaya, S., *see* Ehrlich, B. E.
Biagi, G. L., *see* Paolini, M.
Bigot, M-C., *see* Camsonne, R.
Blasi, F., *see* Fazioli, F.
Blier, P. and de Montigny, C., Current advances and trends in the treatment of depression 220
Blin, N. and Strosberg, A. D., Blin and Strosberg reply, (L) 281
Blin, N., *see* Emorine, L.
Blue, D. R., *see* Ford, A. P. D. W.
Boarder, M. R., A role for phospholipase D in control of mitogenesis 57
Boarder, M. R., Boarder replies, (L) 174
Boarder, M. R., Turner, J. T., Erb, L. and Weisman, G. A., Classification of P_2 purinoceptors, (L) 280
Bond, R. A., *see* Hieble, J. P.
Bowery, N. G., *Peripheral Benzodiazepine Receptors*, (BR) 63
Bradshaw, J., *3D QSAR in Drug Design*, (BR) 469
Brown, C. M., *see* MacKinnon, A. C.
Burks, T. F., Pharmacology in the new era of higher education: view from the USA 283
Burnstock, G., *see* Barnard, E. A.
Bustany, P., *see* Camsonne, R.

C

Camsonne, R., Bigot, M-C., Bustany, P., Pottier, D. and Vergnaud, M., Molecular aspect of HIV-1 resistance to zidovudine and its reversal, (L) 137
Cantelli-Forti, G., *see* Paolini, M.
Carruthers, A. M. and Fozard, J. R., Carruthers and Fozard reply, (L) 14
Challiss, R. A. J., *see* Eglen, R. M.
Chaouloff, F., Complex interactions in 5-HT motor programmes, (L) 444
Chapman, I. D. and Mazzoni, L., Mechanisms of inhibition by cyclosporin A on pulmonary leukocyte accumulation 99
Cirino, G., *see* Wallace, J. L.
Clarke, D. E., *see* Ford, A. P. D. W.
Collingridge, G. L., *see* Watkins, J. C.
Colotta, F. and Mantovani, A., Induction of the interleukin-1 decoy receptor by glucocorticoids, (L) 138
Compton, D., *Marihuana: The Forbidden Medicine*, (BR) 94
Corasaniti, T. M., *see* Bagetta, G.
Cotter, T. G., *Cytotoxic Cells: Recognition, Effector Function, Generation and Methods*, (BR) 165
Cox, R. F., *see* Freedman, J. E.
Coyle, A. J., *see* Anderson, G. P.
Cunningham, F. M., *Xenobiotics and Inflammation*, (BR) 432

D

Dajas, F., *see* Wonnacott, S.
Dashwood, M. R., *Receptor Autoradiography Principles and Practice*, (BR) 392
Davenport, A. P. and Maguire, J. J., Davenport and Maguire reply, (L) 136
Davenport, A. P. and Maguire, J. J., Is endothelin-induced vasoconstriction mediated only by ET_A receptors in humans? 9
Davis, S. S., *Biological Barriers to Protein Delivery*, (BR) 64
de Montigny, C., *see* Blier, P.
Delaney, P. M., *see* King, R. G.
Devane, W. A., New dawn of cannabinoid pharmacology 40
Dickenson, A. H., *see* Dray, A.
Dickenson, A. H., *see* Stanfa, L.
Diemel, L. T. , *see* Tomlinson, D. R.
Dougall, I. G., *see* Robertson, M. J.
Douglas, S. A., Meek, T. D. and Ohlstein, E. H., Novel receptor antagonists welcome a new era in endothelin biology 313
Dray, A., Urban, L. and Dickenson, A., Pharmacology of chronic pain 190

E

Ebashi, S., *see* Godfraind, T.
Edwards, D. R., Cell signalling and the control of gene transcription 239
Edwards, G., *K^+ Channels in Cardiovascular Medicine*, (BR) 350
Eglen, R. M., Reddy, H., Watson, N. and Challiss, R. A. J., Eglen *et al.* reply, (L) 407
Eglen, R. M., Reddy, H., Watson, N. and Challiss, R. A. J., Muscarinic acetylcholine receptor subtypes in smooth muscle 114
Ehrlich, B. E., Kaftan, E., Bezprozvannaya, S. and Beprozvanny, I., The pharmacology of intracellular Ca^{2+} - release channels 145
Eikelenboom, P., Zhan, S. S., van Gool, W. A. and Allsop, D., Inflammatory mechanisms in Alzheimer's disease 447
Emorine, L., Blin, N. and Strosberg, A. D., The human β_3-adrenoceptor: the search for a physiological function 3
Erb, L., *see* Boarder, M. R.
Evans, R. H., *Drug Design for Neuroscience*, (BR) 93

F

Fan, T-P. D., Angiosuppressive therapy for cancer 33
Farndale, R. W., *see* Sage, S. O.
Fasolato, C., Innocenti, B. and Pozzan, T., Receptor-activated Ca^{2+} influx: how many mechanisms for how many channels? 77
Fazioli, F. and Blasi, F., Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? 25

Finazzi-Agrò, A., *see* Bagetta, G.
Fitzgerald, M., *Women Physiologists*, (BR) 31
Flower, R. J. and Rothwell, N. J., Lipocortin 1: cellular mechanisms and clinical relevance 71
Ford, A. P. D. W., Williams, T. J., Blue, D. R. and Clarke, D. E., α_1- Adrenoceptor classification: sharpening Occam's razor 167
Fozard, J. R., *see* Carruthers, A. M.
Freedman, J. E., Waszczak, B. L., Cox, R. F., Liu, J-C. and Greif, G. J., The dopamine D_3 receptor and 7-OH-DPAT, (L) 173
Frölich, J. C., Kirch, W. P., Rietbrock, N., Roots, I. and Gundert-Remy, U., Comments from chairs of institutes of clinical pharmacology in Germany 410

G
Gerskowitch, V. P., Jenkinson, D. and Girdlestone, D., Receptors on the agenda: a symposium to honour Sir James Black 355
Girdlestone, D. and Rosser, M., Looking good 201
Girdlestone, D., Gerhard Zbinden (Obituary) 16
Girdlestone, D., *see* Gerskowitch, V. P.
Godfraind, T., Endothelin receptors in human coronary arteries, (L) 136
Godfraind, T., Netter, K. and Ebashi, S., Welcome to the International Union of Pharmacology in Montréal 202
Goldfarb, P., *In Vitro Biological Systems*, (BR) 30
Grant, T. L., Ohnmacht, C. J. and Howe, B. B., Anilide tertiary carbinols: a novel series of K^+ channel openers 402
Greif, G. J., *see* Freedman, J. E.
Gros, P., *see* Ruetz, S.
Grundemar, L. and Håkanson, R., Neuropeptide Y effector systems: perspectives for drug development 153
Gundert-Remy, U., *see* Frölich, J. C.

H
Habermann, E., Comments from E. Habermann, University of Gießen, Germany 175
Habermann, E., Habermann replies, (L) 411
Håkanson, R., *see* Grundemar, L.
Hall, D. A., *see* Hourani, S. M. O.
Hallam, T. J., *see* Wilkinson, S. E.
Hamon, M., Neuropharmacology of anxiety: perspectives and prospects 36
Harmar, A. J. and Lutz, E., Multiple receptors for PACAP and VIP 97
Harper, D., *see* Robertson, M. J.
Harper, P. A., *see* Okey, A. B.
Harris, B. D., *see* Moody, E. J.
Harro, J., *Behavioural Neuroscience: A Practical Approach, Volume II*, (BR) 199
Hartzell, H. C., *see* Quarmby, L. M.
Harvey, A. L., *see* Jerusalinsky, D.
Henley, J. M., Kainate-binding proteins: phylogeny, structures and possible functions 182
Hibert, M., *see* Hoflack, J.
Hieble, J. P. and Bond, R. A., New directions in adrenoceptor pharmacology 397
Hoflack, J., Trumpp-Kallmeyer, S. and Hibert, M., Re-evaluation of bacteriorhodopsin as a model for G protein-coupled receptors 7
Hollenberg, M. D., Tyrosine kinase pathways and the regulation of smooth muscle contractility 108
Horuk, R., Molecular properties of the chemokine receptor family 159
Hourani, S. M. O. and Hall, D. A., Receptors for ADP on human blood platelets 103
Howe, B. B., *see* Grant, T. L.
Humphrey, P. P. A., Spedding, M. and Vanhoutte, P. M., Receptor classification and nomenclature: the revolution and the resolution 203

I
Idle, J. R., *Genetic Factors in Drug Therapy*, (BR) 309
IJzerman, A. P., *see* Kennedy, C.
Innocenti, B., *see* Fasolato, C.
Iversen, H., *see* Olesen, J.

J
Järv, J., An alternative model for bell-shaped concentration–response curves, (L) 321
Jenkinson, D., *see* Gerskowitch, V. P.
Jenner, S., *see* Sage, S. O.
Jerusalinsky, D. and Harvey, A. L., Toxins from mamba venoms: small proteins with selectivities for different subtypes of muscarinic acetylcholine receptors 424
Jones, H. B., *see* Shaw, I. C.

K
Kaftan, E., *see* Ehrlich, B. E.
Kaumann, A. J., Do human atrial 5-HT_4 receptors mediate arrhythmias? 451
Keen, M., *Fundamentals of Receptor, Enzyme and Transport Kinetics*, (BR) 29
Kenakin, T. P., On the definition of efficacy, (L) 408
Kennedy, C. and IJzerman, A. P., Adenosine and ATP: from receptor structure to clinical applications 311
Kimbel, K. H., *see* Belz, G. G.
King, R. G. and Delaney, P. M., Confocal microscopy in pharmacological research 275
Kirch, W. P., *see* Frölich, J. C.
Klein, W., *see* Stoschitzky, K.
Kokaia, M., *see* Pratt, G. D.
Koob, G. F., *see* Pulvirenti, L.

L
Large, C. H. and Stubbs, C. M., The dopamine D_3 receptor: Chinese hamsters or Chinese whispers? 46
Large, C. H. and Stubbs, C. M., Large and Stubbs reply, (L) 173
Lazareno, S., *GraphPad Prism (version 1.02)*, (SR) 353
Leff, P., *see* Robertson, M. J.
Leff, P., Theoretical treatment of one-agonist–two-receptor systems, (L) 320
Lefkowitz, R. J., Rodbell and Gilman win 1994 Nobel prize for Physiology and Medicine 442
Lemaire, S., *see* Shukla, V. K.
Linden, J., Cloned adenosine A_3 receptors: pharmacological properties, species differences and receptor functions 298
Lindner, W., *see* Stoschitzky, K.
Liu, J-C., *see* Freedman, J. E.
Lodish, H. F., *see* Simonsen, H.
Lutz, E., *see* Harmar, A. J.

M
MacKinnon, A. C., Spedding, M. and Brown, C. M., α_2-Adrenoceptors: more subtypes but fewer functional differences 119
Maguire, J. J., *see* Davenport, A. P.
Maliski, E. G., *Molecular Modelling and Drug Design*, (BR) 395
Mann, J., *The Poisonous Pen of Agatha Christie*, (BR) 307
Mantovani, A., *see* Colotta, F.
Marks, G. S., The history of pharmacology in Canada 205
Martin-Iverson, M., *Methods in Behavioral Pharmacology: Techniques in the Behavioral and Neural Sciences, Volume 10*, (BR) 200
Mazzoni, L., *see* Chapman, I. D.
McDonald, B. J., *see* Bennett, B. M.
McKechnie, K. C. W., *see* Robertson, M. J.
Meek, T. D., *see* Douglas, S. A.
Meurs, H., *see* Roffel, A. F.
Moody, E. J., Harris, B. D. and Skolnick, P., The potential for safer anaesthesia using stereoselective anaesthetics 387
Moore, G. J., Designing peptide mimetics 124
Morley, J., *Handbook of Immunopharmacology*, (BR) 393
Morley, J., K^+ channel openers and suppression of airway hyperreactivity 463
Morris, S. J., *see* Albert, P. R.

N
Netter, K., *see* Godfraind, T.
Nichols, C. G., *Ion Channels in the Cardiovascular System: Function and Dysfunction*, (BR) 470
Nicosia, S., *see* Rovati, G. E.
Nigam, R., *see* Bennett, B. M.
Nisticò, G., *see* Bagetta, G.

O
Ohlstein, E. H., *see* Douglas, S. A.
Ohnmacht, C. J., *see* Grant, T. L.
Okey, A. B., Riddick, D. S. and Harper, P. A., Molecular biology of the aromatic hydrocarbon (dioxin) receptor 226
Olesen, J., Thomsen, L. L. and Iversen, H., Nitric oxide is a key molecule in migraine and other vascular headaches 149
Oliviera, L., Paiva, A. C. M., Sander, C. and Vriend, G., A common step for signal transduction in G protein-coupled receptors 170

P
Page, C. P., Sutter, M. C. and Walker, M. J. A., Wither, whether and whither pharmacology 17
Paiva, A. C. M., *see* Oliviera, L.
Paolini, M., Biagi, G. L., Cantelli-Forti, G. and Bauer, C., Further mechanisms of non-genotoxic carcinogenesis, (L) 322
Parente, L. and Solito, E., Association between glucocorticosteroids and lipocortin 1, (L) 362
Parratt, J. R., Protection of the heart by ischaemic preconditioning: mechanisms and possibilities for pharmacological exploitation 19
Patil, P. N., Comments from P. N. Patil, The Ohio State University, USA 177
Patou, G., *The Search for Anti-Viral Drugs*, (BR) 307
Paul, A., *see* Plevin, R.
Perkins, M., *Molecular Biology and Pharmacology of Bradykinin Receptors*, (BR) 94
Plevin, R. and Paul, A., Evidence against a role for phospholipase D in mitogenesis, (L) 174
Pliska, V., Models to explain dose–response relationships that exhibit a downturn phase 178
Pottier, D., *see* Camsonne, R.

Pozzan, T., *see* Fasolato, C.
Pratt, G. D. and Kokaia, M., *In situ* hybridization and its application to receptor subunit mRNA regulation 131
Pulvirenti, L. and Koob, G. F., Dopamine receptor agonists, partial agonists and psychostimulant addiction 374

Q
Quarmby, L. M. and Hartzell, H. C., Dissection of eukaryotic transmembrane signalling using *Chlamydomonas* 343

R
Ramkumar, V., *see* Beaven, M. A.
Rang, H., William Paton (Obituary) 15
Rangachari, P. K., Quality education for undergraduates in pharmacology: a Canadian experiment 211
Rangachari, P. K., The teaching of pharmacology: needs, challenges and responses for the future 399
Reddy, H., *see* Eglen, R. M.
Reverte, M., Pharmacological effects of β_3-adrenoceptors, (L) 281
Ribeiro, J. A. and Sebastião, A. M., Further evidence for adenosine A_3 receptors, (L) 13
Riddick, D. S., *see* Okey, A. B.
Rietbrock, N., *see* Frölich, J. C.
Robertson, M. J., Dougall, I. G., Harper, D., McKechnie, K. C. W. and Leff, P., Agonist–antagonist interactions at angiotensin receptors: application of a two-state receptor model 364
Roepe, P. D., Indirect mechanism of drug transport by P-glycoprotein, (L) 445
Roffel, A. F., Meurs, H. and Zaagsma, J., Muscarinic acetylcholine receptors and control of smooth muscle tone, (L) 407
Roots, I., *see* Frölich, J. C.
Rosser, M., *see* Girdlestone, D.
Rothwell, N. J., *see* Flower, R. J.
Rovati, G. E. and Nicosia, S., Lower efficacy: interaction with an inhibitory receptor or partial agonism? 140
Rovati, G. E. and Nicosia, S., Rovati and Nicosia reply, (L) 321
Ruetz, S. and Gros, P., A mechanism for P-glycoprotein action in multidrug resistance: are we there yet? 260

S
Sage, S. O., Sargeant, P., Jenner, S. and Farndale, R. W., Tyrosine phosphorylation and Ca^{2+} influx, (L) 282
Sander, C. , *see* Oliviera, L.
Sargeant, P., *see* Sage, S. O.
Saxena, P. R., *see* Bax, W. A.
Schulz, R. and Triggle, C. R., Role of NO in vascular smooth muscle and cardiac muscle function 255
Sebastião, A. M., *see* Ribeiro, J. A.
Seeman, P. and Van Tol, H. H. M., Dopamine receptor pharmacology 264
Shaw, C., *Receptors in the Developing Nervous System (Vol. 1, Growth Factors and Hormones; Vol. 2, Neurotransmitters),* (BR) 351
Shaw, I. C. and Jones, H. B., Mechanisms of non-genotoxic carcinogenesis 89
Shaw, I. C. and Jones, H. B., Shaw and Jones reply, (L) 323
Shukla, V. K. and Lemaire, S., Non-opioid effects of dynorphins: possible role of the NMDA receptor 420
Sibley, D. R., *The G-Protein Linked Receptor FactsBook,* (BR) 431
Simon, W. C., *see* Bennett, B. M.
Simonsen, H. and Lodish, H. F., Cloning by function: expression cloning in mammalian cells 437
Skolnick, P., *Benzodiazepine Dependence,* (BR) 198
Skolnick, P., *see* Moody, E. J.
Solito, E., *see* Parente, L.
Spedding, M., *see* Humphrey, P. P. A.
Spedding, M., *see* MacKinnon, A. C.
Stamford, J. A., *Fraud and Misconduct in Medical Research,* (BR) 308
Stamford, J. A., *Postgraduate Study in the Biological Sciences: A Researcher's Companion,* (BR) 198
Stamford, J. A., *Presynaptic Receptors in the Mammalian Brain,* (BR) 433
Stanfa, L., Dickenson, A. H., Xu, X-J. and Wiesenfeld-Hallin, Z., Cholecystokinin and morphine analgesia: variations on a theme 65
Stemp, G., *Modern Medicinal Chemistry,* (BR) 350
Stevens, E. J., *see* Tomlinson, D. R.
Stewart, A. G., *Pharmacology of the Respiratory Tract,* (BR) 63
Stoschitzky, K., Lindner, W. and Klein, W., Chiral aspects of β-adrenoceptor antagonists, (L) 102
Strange, P. G., Dopamine D_4 receptors: curiouser and curiouser 317
Strosberg, A. D., *see* Blin, N.
Strosberg, A. D., *see* Emorine, L.
Stubbs, C. M., *see* Large, C. H.
Sutter, M. C., *see* Page, C. P.
Szyf, M., DNA methylation properties: consequences for pharmacology 233

T
Taylor, C. W., Ca^{2+} sparks a wave of excitement 271
Tepper, M. A., *Immunosuppressive Drugs: Developments in Anti-rejection Therapy,* (BR) 469
Thomsen, L. L., *see* Olesen, J.
Tomlinson, D. R., Stevens, E. J. and Diemel, L. T., Aldose reductase inhibitors and their potential for the treatment of diabetic complications 293
Torphy, T. J., β-Adrenoceptors, cAMP and airway smooth muscle relaxation: challenges to the dogma 370
Triggle, C. R., *see* Schulz, R.
Trumpp-Kallmeyer, S., *see* Hoflack, J.
Turner, J. T., *see* Boarder, M. R.

U
Upton, N., Mechanisms of action of new antiepileptic drugs: rational design and serendipitous findings 456
Urban, L., *see* Dray, A.
Usherwood, P. N. R., *Nonselective Cation Channels: Pharmacology, Physiology and Biophysics,* (BR) 431

V
Van Tol, H. H. M., *see* Seeman, P.
van Gool, W. A., *see* Eikelenboom, P.
Vanhoutte, P. M., *see* Humphrey, P. P. A.
Vergnaud, M., *see* Camsonne, R.
Vriend, G., *see* Oliviera, L.

W
Wadsworth, R. M., Vasoconstrictor and vasodilator effects of hypoxia 47
Wahlestedt, C., Antisense oligonucleotide strategies in neuropharmacology 42
Walker, M. J. A., *see* Page, C. P.
Wallace, J. L. and Cirino, G., The development of gastrointestinal-sparing nonsteroidal anti-inflammatory drugs 405
Wallis, D. I., 5-HT receptors involved in initiation or modulation of motor patterns: opportunities for drug development 288
Wallis, D. I., Wallis replies, (L) 445
Wang, K. K. W. and Yuen, P-W., Calpain inhibition: an overview of its therapeutic potential 412
Waszczak, B. L., *see* Freedman, J. E.
Watkins, J. C. and Collingridge, G. L., Phenylglycine derivatives as antagonists of metabotropic glutamate receptors 333
Watson, N., *see* Eglen, R. M.
Webb, T. A., *see* Barnard, E. A.
Weisman, G. A., *see* Boarder, M. R.
Wiesenfeld-Hallin, Z., *see* Stanfa, L.
Wilkinson, S. E. and Hallam, T. J., Protein kinase C: is its pivotal role in cellular activation overstated? 53
Williams, T. J., *see* Ford, A. P. D. W.
Wiseman, H., Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances 83
Wonnacott, S. and Dajas, F., Neurotoxins: nature's untapped bounty 1

X
Xu, X-J., *see* Stanfa, L.

Y
Yuen, P-W., *see* Wang, K. K. W.

Z
Zaagsma, J., *see* Roffel, A. F.
Zhan, S. S., *see* Eikelenboom, P.

Subject Index

compiled by Angela Thorne

A
A-fibres 190
ABC transporters, *see* ATP-binding cassette (ABC) membrane transporters
acetylcholine 256
acetylcholine receptors, *see* muscarinic and nicotinic acetylcholine receptors
acetylcholinesterase 1
acid, *see* pH
1S, 3R-ACPD, *see* 1-aminocyclopentane-1, 3-dicarboxylic acid
acquired immune deficiency syndrome (AIDS) 138 (L), 362 (L)
ACTH, *see* adrenocorticotrophic hormone
activator protein 1 (AP-1) 234, 239
active transport (drugs) and P-glycoprotein 263, 445 (L)
acute pain 191
adenosine 21, 360
adenosine receptors
  A_3 13 (L), 14 (L), 298
  expression cloning of 311
  in heart 361
  and ischaemic preconditioning 21
adenylate cyclase
  and ADP 104
  and β_3-adrenoceptors 6
  concentration–response curves for 144, 321 (L)
  history of research into 442
  interaction with G_α subunits 253
  and mating responses (*Chlamydomonas*) 347
  and M_2 muscarinic acetylcholine receptors 116
adipose tissue
  β_3-adrenoceptors in 3, 281 (L)
ADP receptors 103
α-adrenoceptors
  α_1 167, 397
  α_2 119, 196, 223, 397
β-adrenoceptors
  antagonists, chiral aspects of 102 (L)
  β_2, and mast cells 100
  β_3, physiological function of 3, 281 (L)
  and cAMP in bronchodilation 370
  characterization and ligand design 355
  and 5-HT_4 receptors 454
  in smooth muscle 118, 407 (L)
  subclassification of 397
adrenocorticotrophic hormone (ACTH) 75
AFDX116 117, 407 (L)
agglutinins 347
aggregation, platelet 103, 417, 452
aggregin 106
agonists
  and Ca^{2+} channel activation 80
  model for interaction with antagonists 364
  muscarinic toxins as 427
  and peptide mimetic design 124
  (see also adenosine receptors, α-adrenoceptors, dopamine, endothelin, 5-HT, and muscarinic acetylcholine)
Ah (aromatic hydrocarbon) locus (mouse) 230
AH receptor, *see* aromatic hydrocarbon receptor
AIDS, *see* acquired immune deficiency syndrome
airway epithelium
  and hyperreactivity 464
  and inflammation 99, 324
  intercellular Ca^{2+} waves in 273
airway hyperreactivity
  and K^+ channel openers 463
airway smooth muscle
  and β-adrenoceptors 370, 407 (L)
  and asthma 463
Alberta
  pharmacology in 209
aldose reductase inhibitors
  and diabetes mellitus 293
alkyltrimethylammonium compounds
  concentration–response curves for 143
allergic disease, *see* asthma
allergic immune memory
  and IL-4 328
allodynia 191
allosteric coupling
  in G protein-coupled receptors 170
alternative splicing
  and receptor variation 131
Alzheimer's disease
  and calpain 416
  inflammatory mechanisms in 447
amantadine 376
Ames test 89
amiloride 28
amino acids, critical
  in adenosine receptors 298, 311
  in β-adrenoceptors 4
  in chemokine receptors 163
  in endothelin receptors 313
  in G protein-coupled receptors 122, 170
  in kainate receptors 184
  and ligand–receptor interaction 357
  in muscarinic toxins 428
  in neurotoxin structure 1
  in P_2 purinoceptors 311
1-aminocyclopentane-1,3-dicarboxylic acid (1S, 3R-ACPD) 333
N^6-2-(4-amino-phenyl)ethyladenosine (APNEA) 301
1-amino-4-phosphonobutanoic acid (AP4) 333
2-amino-3-phosphonopropionic acid (AP3) 333
AMPA receptors 182, 462
amphetamines 374
amyloid precursor peptide 447
anaesthetics
  stereoselectivity of 387
analgesia
  and adrenoceptor agonists 399
  and cholecystokinin 65
  and dynorphin A 420
anandamide 40
angiogenesis
  in cancer 33, 215
angiosuppressives 33
angiotensin-converting enzyme inhibitors and NO 258
angiotensin II 112, 125
angiotensin receptors 364
anilide tertiary carbinols
  as K^+ channel openers 402
animal seizure models 460
annexin-1 (lipocortin-1) 71
anorexia
  and neuropeptide Y 154
antagonists
  dynamics of 364
  model for interaction with agonists 364
  negative efficacy of 408 (L)
  and peptide mimetic design 124
  (*see also* adenosine, α-adrenoceptors, β-adrenoceptors, cholecystokinin, DNA methyltransferase, dopamine, endothelin, 5-HT, metabotropic glutamate receptors, neuropeptide Y, P_2-purinoceptors, and urokinase-type plasminogen activator)
anti-androgens
  and K^+ channel openers 402
antibodies
  in analysis of G protein action 250
  as angiosuppressors 33
  to Ca^{2+}-release channels 148
  and confocal microscopy 275
  on sterically stabilized liposomes 217
anticancer drugs
  DNA methyltransferase antagonists as 235
  tamoxifen 86
  targeted liposomal delivery of 215
antidepressants 220
antiepileptic drugs 456
antigens
  and CD4+ helper T cells 324
anti-inflammatory drugs
  for Alzheimer's disease 449
anti-metastatic therapy
  activator receptor antagonists 28
  and tamoxifen 86
  and targeted immunoliposomal drug delivery 219
  and urokinase-type plasminogen antioestrogens 87
antioxidants 83
antiparkinson drugs 264
antipsychotic drugs 264, 317
antisense oligonucleotides
  in DNA methyltransferase 237
  in pharmacology 42
  in study of protein kinase C 56

in study of signal transduction 250
antisense RNA 252
anti-thrombotic agents
calpain inhibitors as 417
NO-releasing NSAIDS as 406
anti-viral drugs 307 (BR)
anxiety 36, 157
anxiolytics 36, 153
AP-1, *see* activator protein 1
AP3, *see* 2-amino-3-phosphonopropionic acid
AP4, *see* 1-amino-4-phosphonobutanoic acid
arginine switch (G protein-coupled receptors) 170
aromatic hydrocarbon (AH) receptor 226
aromatic-hydrocarbon-receptor-nuclear-translocator (ARNT) protein 226
aromatic-hydrocarbon-responsive elements (AHREs) 226
arrhythmias
and β-adrenoceptors 358
and 5-HT 452
and ischaemic preconditioning 20, 304
arterial smooth muscle
and hypoxia 47
arteries
endothelin receptors in 381
and hypoxia 47
and NO-induced headache 149
(*see also* cerebral, coronary and pulmonary artery)
arthritis
and calpain 418
asthma
and adenosine 13 (L), 300, 312
and $CD4^+$ helper T cells 324
and cyclosporin A 99
and glucocorticosteroids 329
and K^+ channel openers 463
atherosclerosis
and endothelin 314
and hypoxia 52
and tamoxifen 85
ATP 260, 311
ATP-binding cassette (ABC) membrane transporters 260
ATP channels 261
ATP-dependent K^+ channels 23, 463
ATP receptors, *see* P_2-purinoceptors
atrial fibrillation
and 5-HT 452
atrium
5-HT_4 receptors in 451
autoradiography
in expression cloning 438
with muscarinic toxins 427
of receptors 392 (BR)
autoreceptors 121, 221
azacytidine 235
AZPET-ADP 107

B

β/A4 peptide 447
B cells 324
bacterial sepsis
and NO 257
bacteriorhodopsin
as model for G protein-coupled receptors 7, 170
basic fibroblast growth factor (bFGF) 25, 33
basic helix–loop–helix domains 229
Bcl3 243
behavioural studies 199 (BR), 200 (BR)
benoxathian 167
benzodiazepines 36, 198 (BR)
benzodiazepine receptors 63 (BR)
Bergmann glia
kainate-binding proteins in 187
biomedical sciences
and education 284
biotransformation
of organic nitrates 245
BK_{Ca} channels 372
Black, James
symposium in honour of 355
bladder
K^+ channel openers in 403
blood flow
and NO release 256
blood platelets
and ADP receptors 103
blood vessels (human)
endothelin receptors in 384
BMS182874 315
bone cells
and endothelin 1 316
bosentan 315
botulinum toxins 2
bovine rhodopsin 7
BQ123 9, 313, 380
BQ788 315, 380
BQ3020 9, 382
bradykinin
and chronic pain 191
and ischaemic preconditioning 21
and NO 258
bradykinin receptors 94 (BR), 191
brain
confocal microscopy of 279
lipocortin-1 in 73
NO synthase in 255
presynaptic receptors in 433 (BR)
brain injury
and calpain 415
brainstem
5-HT receptors in 290
breast cancer
and tamoxifen 83
British Colombia
pharmacology in 207
BRL37344 4
bromocriptine 375
bronchoconstriction 300, 312
bronchodilation 370
bronchospasm 464
bulimia
and neuropeptide Y 157

C

C-fibres 190
Ca^{2+}
and airway hyperreactivity 464
and calpain 412
and cholecystokinin action 65
and EGF action 110
and 5-HT in arrhythmias 453
hypnoxic contraction by 51
inhibition of influx via G_α subunits 253
intracellular-store-dependent influx 77, 103, 271, 282 (L)
and NO 255
and M_3 muscarinic acetylcholine receptors 116
and platelet activation 103
and protein kinase C 53
and protein kinase G in bronchodilation 371
receptor-activated influx 80
and signal transduction in *Chlamydomonas* 344
Ca^{2+} channels
and antiepileptic drugs 461
Ca^{2+}-release-activated 77, 145, 271
and deflagellation (*Chlamydomonas*) 347
G protein-operated 80
and 5-HT_4 receptors in arrhythmias 453
inhibition of 2
second-messenger-operated 81, 145
Ca^{2+} imaging
using confocal microscopy 275
Ca^{2+}-influx factor (CIF) 79, 274
Ca^{2+} sparks 271
Ca^{2+} stores
and ADP 103
and Ca^{2+}-release channels 145, 271
characterization of 80
and tyrosine phosphorylation 282 (L)
Ca^{2+} waves 271
caffeine
and Ca^{2+}-release channels 145
calcitonin gene-related peptide (CGRP) 191
calcium channels, *see* Ca^{2+} channels
calpain
pathological roles of 412
calpain inhibitors 412
calpastatin 413
calpeptin 413
Canada
pharmacology in 202, 205, 211
cancer
angiosuppressive therapy for 33
and DNA methylation 235
and drug delivery by liposomes 215
and non-genotoxic carcinogenesis 89
and tamoxifen 83
and uPA 25
Candida
and tamoxifen 87
cannabimimetic compounds 40
cannabinoid receptors 40
carbon monoxide
as cytochrome P450 inhibitor 247
2s,1's,2's-2-(2'-carboxycyclopropyl)glycine (L-CCG-I) 333
s-4-carboxy-3-hydroxyphenylglycine (s-4C3HPG) 334
s-4-carboxyphenylglycine (s-4CPG) 334
carcinogenesis, non-genotoxic 89, 322 (L), 323 (L)
carcinogens 89
carcinoid tumours
and arrhythmias 452
cardiac injury
and ischaemic preconditioning 21, 304
cardiac ischaemia
and calpain 416
cardiac smooth muscle
and atrial 5-HT_4 receptors 451
Ca^{2+} sparks in 271
and ischaemic preconditioning 20, 304
and NO 258
cardioprotection
by adenosine receptor ligands 312
by endothelin 314
by tamoxifen 85
cardiovascular system
ion channels in 470 (BR)
K^+ channels in 350 (BR)
and neuropeptide Y 154
and NO 258
cataracts
and calpain 417
catecholamines 122, 221, 358
CC chemokine receptors 160
L-CCG-I, *see* 2s,1's,2's-2-(2'-carboxycyclopropyl)glycineCD4+ helper T cells 99, 324
$CD8^+$ T cells 326
cell death
and calpain 414
cell differentiation
and the aromatic hydrocarbon receptor 229
DNA methylation in 233
and lipocortin-1 73, 362 (L)
cell growth
and the aromatic hydrocarbon receptor 228
and lipocortin-1 73
cell migration
and uPA 25

central nervous system
and neuropeptide Y 154
central pain 196
central pattern generators 289
centrin 347
cerebellum 146, 186
cerebral artery
and hypoxia 48
cerebral cortex
muscarinic acetylcholine receptors in 425
cerebral ischaemia
and calpain inhibitors 414
cerebrovascular disease
and endothelin 1 315
CFTR (cystic fibrosis transmembrane conductance regulator) 260
CGP12177 4
CGP35348
CGRP, *see* calcitonin gene-related peptide
S-4C3HPG, *see* S-4-carboxy-3-hydroxyphenylglycine
chemokine receptors 159
chemotaxis
and Ca^{2+} waves 272
chick
kainate-binding proteins in 186
chirality
of β-adrenoceptor antagonists 102 (L)
of anaesthetics 387
of organic nitrate biotransformation 246
of phenylglycine derivatives 335
Chlamydomonas
signal trandsduction in 343
chloroethylclonidine 167
4-[*N*-(chlorophenyl)carbamoyloxy]-4-pent-2-ynyl-trimethylammonium (CP) 427
cholecystokinin 65, 196
cholecystokinin (CCK) receptors
and anxiety 38
and gastric acid secretion 357
and morphine analgesia 65
cholesterol 84
Christie, Agatha 307 (BR)
cisapride 452
chronic injury 33
chronic pain 190, 420
cimetidine 248
Cl^- channels
and anaesthetics 388
and antiepileptic drugs 457
and Ca^{2+} waves 272
and P-glycoprotein 261
clinical pharmacology 175, 410 (L), 411 (L)
clonidine 119
cloning vectors 437
clostridial toxins 2
clozapine 267, 317
cluster headache 151
*p*CMBS 105
cocaine 374
colon carcinoma (murine)
drug delivery to by liposomes 216
commitment (T_H2 cells) 326
complement
and Alzheimer's disease 447
computers
and education in pharmacology 401
concentration–response curves
and antagonist dynamics 364
with downturn phase 178
and ligand–receptor interaction 140, 320 (L), 321 (L)
confocal microscopy 275
conotoxins 2
controls
in antisense oligonucleotide technology 44
in expression cloning 440
coronary artery
endothelin receptors in 136 (L)
and hypoxia 48
tyrosine kinase pathway in 113
coronary vasospasm 52
cortex
α_2-adrenoceptors in 120
corticosteroids 37
corticotrophin-releasing factor (CRF) 37, 75
COS cells 437
CP, *see* 4-[*N*-(chlorophenyl)carbamoyloxy]-4-pent-2-ynyl-trimethylammonium
S-4CPG, *see* S-4-carboxyphenylglycine
CRE (cAMP response element) 241
cromakalim 402, 462, 464
cromoglicate disodium 467
crystallins 417
curriculum, pharmacology
in McMaster University (Ontario) 211
in the USA 286
CXC chemokine receptors 159
cyclic ADP-ribose 271
cyclic AMP
in β-adrenoceptor action 370
inhibition of production via G_α subunits 253
and signal transduction in *Chlamydomonas* 344
cyclic AMP response element (CRE) 241
cyclic GMP 255
cyclooxygenase inhibitors 49, 191, 405
cyclosporin A 99
CYP1A1 gene
and the aromatic hydrocarbon receptor 227
cystic fibrosis 312
cystic fibrosis transmembrane conductance regulator, *see* CFTR
cytochrome P450
and biotransformation of organic nitrates 247
and Ca^{2+} influx 80
and non-genotoxic carcinogenesis 322 (L), 323 (L)
cytochrome P450 inhibitors 248
cytokines
and cyclosporin A 99
effects on gene expression 239
and hyperalgesia 191
and inflammation 432 (BR)
and lipocortin-1 75
and NO 255
and T_H2 cells in allergy and asthma 324
cytosines
methylation of 233
cytoskeleton
and Alzheimer's disease 448
cytosol
Ca^{2+}-influx factors in 79
cytotoxic cells 165 (BR)

D

4-DAMP 114
data analysis
concentration–response curves for 140, 178, 320 (L), 321 (L)
GraphPad Prism (version 1.02) 353 (SR)
DCG-IV, *see* (2S,1'R,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl)glycine
decitabine 235
deflagellation (*Chlamydomonas*) 347
demethylation (DNA) 234
α-dendrotoxin 1
dentate gyrus 134
depression 157, 220
depolarization (neuronal)
and metabotropic glutamate receptors 336
desensitization (receptor)
and antidepressants 221
development (nervous system)
receptor expression during 351 (BR)
DHPG, *see* 3,5-dihydroxyphenylglycine
diabetes mellitus 293
diabetic neuropathy 295
diacylglycerol (DAG)
and Ca^{2+} waves in cell migration 272
and EGF actions in smooth muscle 111
and platelet aggregation 104
and protein kinase C 53, 58
(2S,1'R,2'R,3'R(-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV) 333
differentiation, *see* cell differentiation
3,5-dihydroxyphenylglycine (DHPG) 333
dioxin receptor, *see* aromatic hydrocarbon (AH) receptor
dioxin-responsive elements (DREs) 226
(+)-*cis*-dioxolane 116
diphenyleneiodonium sulphate 248
dissociation constants
of dopamine receptor ligands 266, 318
DNA analogues
in antisense oligonucleotide technology 42
DNA-binding proteins
see aromatic hydrocarbon receptor
DNA methylation 233
DNA methyltransferase 233
DNA probes
for *in situ* hybridization 131
cDNAs
isolation by expression cloning 437
dopamine 37, 374
dopamine receptors
coupling with G_α subunits 253
D_3 46 (L), 173 (L)
D_4 317
pharmacology of 264
and psychostimulant addiction 374
S-DOX (doxorubicin in sterically stabilized liposomes) 216
doxorubicin 216
7-OH-DPAT 173 (L)
8-OH-DPAT 288
Dp proteins (black mamba) 426
DPCPX 13 (L), 301, 361
3D QSAR, *see* three-dimensional quantitative structure–activity relationships
droloxifene 87
drugs
anticancer 86, 215, 235
antidepressants 220
antiepileptic 456
immunosuppressive 469 (BR)
and the nature of pharmacology 17, 211, 285, 399
and pharmacogenetics 309 (BR)
resistance to by P-glycoprotein 260, 445 (L)
use in crime fiction 307 (BR)
drug abuse 198 (BR), 374
drug delivery
of angiosuppressors 35
barriers to 64 (BR)
targeted, using liposomes 215
drug design
for anxiety 37
bacteriorhodopsin as model 7
general 93 (BR), 357, 394 (BR)
and medicinal chemistry 350 (BR)
and molecular modelling 359, 394 (BR)
of peptide mimetics 124
of protein kinase C inhibitors 56
3D QSAR in 469 (BR)
of tamoxifen derivatives 87
of T_H2 suppressors 326
drug-metabolizing enzymes
and the aromatic hydrocarbon receptor 229
Duffy blood-group antigen 162
dynorphin A 420

E
E64 413
eating disorders
and neuropeptide Y 157
EC_{50} 141
ECRF3 (viral protein) 162
ectonucleotidases
and P_{2x}-purinoceptor ligands 311
EDHF, *see* endothelium-derived hyperpolarizing factor
EDRF (endothelium-derived relaxing factor), *see* NO
education (in pharmacology)
in Australia 176
in Canada 205, 211
general 399
in Germany 175, 410 (L), 411 (L)
in the UK 17
in the USA 177, 283
EGF, *see* epidermal growth factor
efficacy (ligand) 408 (L)
electroconvulsive shocks
and depression 224
electron diffraction maps 8
electrophysiological systems
in *Chlamydomonas* 345
effects of phenylglycines on 334
Elk-1 240
enantioselectivity, *see* chirality
endothelins
and hypoxia 50
and phospholipase D 60
and vasoconstriction 9, 136 (L)
endothelin receptors
antagonists of 313
classification of 313, 379
and vasoconstriction 9, 136 (L)
endothelin converting enzyme 1 313
endothelium
and cyclosporin A 100
endothelin receptors in 313
and hypoxia 49
and NO 255
endothelium-derived factors
and hypoxia 49
and ischaemic preconditioning 21
see also NO
endothelium-derived hyperpolarizing factor (EDHF) 256
endothelium-derived relaxing factors (EDRFs), *see* NO and EDHF
endotoxin shock
and NO 257
enzyme kinetics 29 (BR)
eosinophils 99, 272, 324
epalrestat 297
S-EPI (sterically stabilized liposomal epirubicin) 216
epidermal growth factor (EGF)
and smooth muscle 108
epilepsy
drugs for 456
and dynorphins 422
and *in situ* hybridization 134
epithelial cells, *see* airway epithelium
erabutoxin-a 1
ergosterol 85
erythrocyte chemokine receptor 162
erythropoietin receptor
cloning of 438
7-ethoxyresorufin 248
excitation (neuronal)
and metabotropic glutamate receptors 336
excitatory amino acid receptors, *see* AMPA, kainate, NMDA and metabotropic glutamate receptors, excitotoxicity and calpain inhibitors 414
and dynorphin A 421
excretion (fluid)
and α_2-adrenoceptors 123
exocytosis
and neurotoxins 2
exotoxin CM101
as angiosuppressor 35
EXP3174 126
EXP3892 368
EXP6155 364
expression cloning 182, 311, 437
extracellular matrix
and Alzheimer's disease 448
eyespot (*Chlamydomonas*) 343

F
fasciculin 1
Fcε receptor 325
felbamate 459
fenoterol 467
fertilization
and Ca^{2+} 271
bFGF, *see* basic fibroblast growth factor
p-F-HHSiD 115
fibre-optic confocal microscopy 276
fibrinogen receptors 103
fictive locomotion 288
flagella function (*Chlamydomonas*) 344
flexor-reflex afferents
and motor patterns 291
fluid excretion
and α_2-adrenoceptors 122
fluorescent dyes
and confocal microscopy 275
c-*fos*
and cell signalling 239
FR139317 10, 381
frog
kainate-binding proteins in 186
fructose
and the sorbitol pathway 294
FSBA 106

G
G proteins
and activation of I_{CRAC} 79
antisense 'knockout' of 250
binding to receptors 171
history of research into 442
and phospholipase D 60
and platelet activation by ADP 103
see also individual types
G_α
antisense 'knockout' of 251
G_i
and adenosine receptors 23
and adenylate cyclase 104
history of research into 443
and M_2 muscarinic acetylcholine receptors 116
G_q
and M_3 muscarinic acetylcholine receptors 116
G_s
and β-adrenoceptor action 370
history of research into 443
G protein-coupled receptors
for acetylcholine 424
for adenosine 302, 311
for ATP 67, 280 (L), 311
bacteriorhodopsin as model for 7, 170
for dopamine 317
general 431 (BR)
and growth factors 60
for IL-8 160
and muscle contraction 112
for neuropeptide Y 155
and phospholipase D 60
and platelet aggregation 103
signal transduction in 170
for VIP 97
GABA receptors
and anaesthetics 388
and antiepileptic drugs 456
and anxiety 36
and pain 195
regulation in kindling 134
gabapentin 457
gallamine 114
gastric acid secretion 356
gastrointestinal injury
and NSAIDS 405
gene expression
control by cell signalling 239
and DNA methylation 233
of endothelin 1 313
of endothelin receptors 313, 380
in epilepsy 134
of IL-4 331
inhibition by antisense oligonucleotides 42
of kainate receptor subunits 183
of P-glycoproteins 260
of P_{2Y}-purinoceptor 67
regulation by aromatic hydrocarbon receptor complexes 227
gene therapy
for angiosuppression 35
genistein 110
GH_4C_1 pituitary cells 252
Gilman, Al (1994 Nobel prize) 442
cGMP
and ischaemic preconditioning 22
glibenclamide 402
glucocorticoids
and asthma 329
and IL-1 138 (L), 139 (L)
and lipocortin-1 71, 362 (L)
glucose
and aldose reductase 293
GluR subunits 183
glutamate receptors
and chronic pain 193
expression cloning of 182
and neurotoxins 2
(*see also* AMPA, kainate, metabotropic glutamate and NMDA receptors)
glutathione reductase 295
glutathione-*S*-transferases 245
glutathione-*S*-transferase inhibitors 247
glycaemia
in diabetes mellitus 293
glycerol trinitrate 149, 245
glycoproteins 103, 260
glycosyl-phosphatidyl-inisitol-anchored proteins 27
goldfish
kainate-binding proteins in 186
gp120 362 (L)
GR113808A 451
granulocytes 100
granulocyte–macrophage colony-stimulating factor (GM-CSF) 99, 324, 437
GraphPad Prism (version 1.02) 353 (SR)
growth factors
and angiogenesis 33
and carcinogenesis 90
effects on gene expression 239
and phospholipase D 57
and receptors during development (BR) 351
and tyrosine kinase pathways 108
growth-regulatory proteins
and the aromatic hydrocarbon receptor 229
guanine nucleotides 188, 443
guanylate cyclase activators 245

H
H7 53
headache
and NO 149
heart
and adenosine 312, 360

Ca^{2+} in 271
and calpain 416
and 5-HT 451
and ischaemic preconditioning 19, 304
and NO 258
and tamoxifen 85
(*see also* cardiovascular system)
heat shock protein 90
and the aromatic hydrocarbon receptor 226
helices (transmembrane) 7, 358
helper T cells 99, 324
heparin 33, 145
hepatocyte growth factor
and urokinase-type plasminogen activator 26
heterokaryons (*Chlamydomonas*) 343
heteromeric configurations
of aromatic hydrocarbon receptors 227
of kainate receptor subunits 183
himbacine 115
hippocampus
and dynorphin A 422
Hirt procedure
in expression cloning 437
histamine
and adenosine receptors 300
and airway hyperreactivity 464
and headache 150
and inflammation 191
histamine receptors 356
history
of G protein research 442
of pharmacology in Canada 205
HIV, *see* human immunodeficiency virus
HL-60 leukocytic cells 254
homologous recombination 45
homologues
α_2-adrenoceptor subtypes as 120
hormones
effects on gene expression 239
and endothelin 1 316
and receptors during development 351 (BR)
(*see also* named hormones)
host cells
for expression cloning 437
s-3HPG, *see* s-3-hydroxyphenylglycine
5-HT
and anxiety 37
and depression 220
effects on the heart 451
and neuropeptide Y 157
and pain 191
and platelet aggregation 103
5-HT receptors
agonist–antagonist interactions at 368
and anxiety 38
atrial (human) 451
and clozapine 268
and depression 221
and motor patterns 288, 444 (L), 445 (L)
signal transduction by 250
HU243 40
human immunodeficiency virus (HIV) 137 (L), 362 (L)
hybridization
in antisense oligonucleotide technology 42
in situ, and confocal microscopy 276
in situ, and receptor regulation 131
s-3-hydroxyphenylglycine (s-3HPG) 334
4-hydroxytamoxifen 85
hyperalgesia
and chronic pain 191
and dynorphin A 420
hyperexcitability
and pain 193
hypertension
and adenosine A_3 receptors 301
and endothelin receptors 314
and inhaled NO 258
and neuropeptide Y 158
hypertonicity
and aldose reductase 293
hypomethylation (DNA)
and cancer 235
hypothalamic–pituitary–adrenal axis
and lipocortin-1 75
hypoxia 47, 151

I

I_{CRAC} (Ca^{2+}-release-activated Ca^{2+} current) 77
IκB protein 243
IC_{50} 141ICI118551 5, 356
ICI164384 87
ICI182780 87
idazoxan 119
imaging (confocal) 276
imidazoline 122, 125
immediate–early genes 239
immune system
in allergy and asthma 324
and anxiety 37
cannabinoid receptors in 40
and chemokine receptors 159
and cyclosporin A 99
and NO 255
and pain 191
and protein kinase C inhibitors 53
immunocytochemical studies
using confocal microscopy 275
immunoglobulin E 324
immunoliposomes 217
immunopharmacology 393 (BR)
immunosuppressive drugs 469 (BR)
imperatoxin 148
indometacin 110
industry
and pharmacology 400
infarcts
and calpain 416
and ischaemic preconditioning 19, 304
inflammation
and adenosine 300, 312
and airway hyperreactivity 464
and $CD4^+$ helper T cells 99, 324
and cholecystokinin 65
and chronic pain 190
and cyclosporin A 99
and dynorphin A 420
and glucocorticoids 138 (L)
and lipocortin-1 73
and NSAIDS 191, 405
and xenobiotics 432 (BR)
ingestive behaviour
and neuropeptide Y 153
inhibitory receptors
and antiepileptic drugs 456
and concentration–response curves 140, 321 (L)
in motor patterning 290
injury, *see* brain, cardiac, chronic, gastrointestinal, nerve, and spinal cord injury
inositol (1,3,4,5)-tetraphosphate (IP_4)
and Ca^{2+} channels 80, 271
inositol (1,4,5)-trisphosphate (IP_3)
and Ca^{2+} influx 77, 103, 271
insects
kainate-binding proteins in 187
in situ hybridization 131, 276
insulin related substrate-1 330
integrins
and Alzheimer's disease 448
interferons 242, 327
interferon-stimulated gene factors (ISGFs) 242
interleukins
in allergy and asthma 324
and Alzheimer's disease 449
and cyclosporin A 99
and inflammation 191
and lipocortin-1 75
(*see also* individual interleukins)
interleukin 1 (IL-1) receptors 138 (L), 139 (L)
interleukin 4 (IL-4) 99, 330
interleukin 4 (IL-4) receptor 330
interleukin 5 (IL-5) 99, 324
interleukin 8 (IL-8) 159
interleukin 8 (IL-8) receptors 160
intracellular adhesion molecule-1 (ICAM-1) 100
in vivo imaging
and confocal microscopy 277
N^6-(3-iodo-4-aminobenzyl)adenosine (I-ABA) 301
ion channels
and anaesthetics 388
in the cardiovascular system 470 (BR)
and neurotoxins 2
nonselective, cation channels 431 (BR)
and pain 190
and platelet aggregation 107
(*see also* Ca^{2+}, Cl^-, K^+ and Na^+ channels)
ion imaging
using confocal microscopy 275
IP_3, *see* inositol (1,4,5)-trisphosphate
IP_3 receptor 145, 271
IP_4, *see* inositol (1,3,4,5)-tetraphosphate
ipratropium bromide 467
IRL1038 10, 382
IRL1620 382
ischaemia
and adenosine receptor ligands 312
and headache 152
and lipocortin-1 75
preconditioning for 19, 304
(*see also* cardiac and cerebral ischaemia)
ISGFs, *see* interferon-stimulated gene factors
isoflurane 387
isoidide dinitrate 246
isoprenaline 116

J

JAK (just another kinase) proteins 242, 331
Jun
and DNA methylation patterns 236

K

K252a 53
K^+ channels
in airway hyperreactivity 463
and anilide tertiary carbinols 402
and antiepileptic drugs 461
ATP-dependent 23, 463
in cardiovascular medicine 350 (BR)
and cyclic AMP 372
and endothelium-derived relaxing factors 256
and hypoxia 51
inhibition of 1
KA subunits 183
kainate receptors 182, 462
Kamposi's sarcoma
drug delivery to by liposomes 217
kidney cells
aldose reductase in 293
kindling 134, 460
kinetics
of concentration–response curves 140, 178, 320 (L), 321 (L)

L

L365260 357
labelling (probes)
for *in situ* hybridization 131
lamotrigine 459
laser-scanning confocal microscopy 276
Lazdunski, Michel (Advisory Editorial Board) 12

LDL, *see* low-density lipoproteins
learning programmes
  for education in pharmacology 211, 286, 400
Leff, Paul (Advisory Editorial Board) 12
Lennox–Gastaut syndrome 461
leukocytes
  and chemokine receptors 159
  and cyclosporin A 99
leupeptin 413
levetiracetam 462
ligand–receptor interaction
  analysis of 355
  of aromatic hydration (AH) receptor 226
  concentration–response curves for 140, 320 (L), 321 (L)
  of cytokine receptors 164
  of dopamine receptors 318
  and ligand efficacy 408 (L)
  relationships with a downturn phase 178
  two-state receptor model for 364
lipid metabolism
  and β_3-adrenoceptors 3, 281 (L)
  and tamoxifen 84
lipocortin-1 (annexin-1) 71, 362 (L)
liposomes, long-circulating
  for targeted drug delivery 215
lipoxygenase products
  and hypoxia 50
lisuride 376
lithium
  and antidepressants 225
locomotion
  and adenosine A_3 receptors 302
  and 5-HT receptors 288, 444 (L), 445 (L)
long-term depression (LTD) 341
long-term potentiation (LTP) 339
losartan 125, 364
low-density lipoproteins (LDL) 83
LTD, *see* long-term depression
LTP, *see* long-term potentiation
lung
  adenosine receptors in 300, 312
  biology of 63 (BR)
  and $CD4^+$ helper T cells 324
  and cyclosporin A 99
  and hypoxia 47
lysophosphatidic acid
  and phospholipase D 59

M

m1-toxin 426
macrophages
  No synthase in 255
macrophage inflammatory protein (MIP) 159
major histocompatibility complex
  class II 324
mamba toxins (MTs) 1, 424
mammals
  kainate-binding proteins in 189
mammary carcinoma (murine)
  drug delivery to by liposomes 216
Manitoba
  pharmacology in 210
marihuana
  therapeutic use of 94 (BR)
Maritimes
  pharmacology in 207
mast cells
  adenosine receptors in 13 (L), 300
  and cyclosporin A 99
  and cytokines 325
  I_{crac} in 78
mastoparam
  and deflagellation (*Chlamydomonas*) 347
mating responses (*Chlamydomonas*) 347
maximal electroshock seizure (MES) test 460
McMaster University (Ontario)
  pharmacology in 206, 211
McNA343 427
MCPG, *see* α-methyl-4-carboxyphenylglycine
MDL28170 413
MDR, *see* multidrug resistance
mdr genes 260
MDRF, *see* muscle-derived relaxing factor
medial hyperstriatum ventrale
  kainate-binding proteins in 188
medical professions
  and pharmacology 400, 410 (L), 411 (L)
medicinal chemistry 350 (BR)
melanoma growth-stimulating activity (MGSA) 159
melting temperature (DNA)
  and *in situ* hybridization 133
membranes
  modulation by tamoxifen 84
memory
  and anxiety 39
  (*see also* long-term potentiation)
metabolism
  of organic nitrates 245
metabotropic glutamate receptors
  antagonists for 333
  for kainate 188
metacholine 463
metastasis
  and tamoxifen 86
  and targeted liposomal drug delivery 219
  and uPA 25
methoctramine 115
methylation (DNA) 233
α-methyl-4-carboxyphenylglycine (MCPG) 334
α,β-methylene ATP 311
α-methyl-*para*-tyrosine (α-MPT) 220
methylscopolamine 426
2-methylthioADP 106, 311
5-methylurapidil 167
metyrapone 248
microglia
  in Alzheimer's disease 448
microtubule dynamics (*Chlamydomonas*) 347
migraine 149
MIP, *see* macrophage inflammatory protein
MIP1α receptor 162
mitogen-activated protein (MAP) kinases
  and cell signalling 239
  and endothelin 315
  and phospholipase D 61, 174 (L)
mitogenesis
  and endothelin 315
  and phospholipase D 57, 174 (L)
MK912 120
MKS492 467
Mn^{2+}
  and Ca^{2+} store depletion 78
modelling
  agonist–antagonist interactions 364
  in angiogenesis research 33
  animal seizures 460
  anxiety 36
  concentration–response curves 140, 178, 320 (L), 321 (L)
  and drug design 394 (BR)
  G protein-coupled receptors 7, 170
  long-term potentiation 341
  neuropeptide Y antagonists 157
  pain 65
  receptor structure 358
  tamoxifen structure 84
molecular biology
  of adrenoceptor types 397
  of α_2-adrenoceptors 119
  and analysis of agonist action 360
  of the aromatic hydrocarbon receptor 229
  of dopamine receptors 264
  to manipulate *Chlamydomonas* 343
  and pharmacology 18, 175, 176, 285, 411 (L)
molecular cloning
  of adenosine receptors 298, 311
  of α_1-adrenoceptors 167
  of the aromatic hydrocarbon receptor 229
  of dopamine receptors 264
  by function 437
  of IL-8 receptors 160
  of kainate receptors 182
  of MIP1α receptor 162
  of P_2 purinoceptors 67, 311
  of VIP receptors 97
molecular lipophilicity potential (MLP) 359
molecular probes
  for *in situ* hybridization 131
monoamines
  as antidepressants 220
monoamine oxidase inhibitors 223
monocyte chemotactic protein 1 (MCP-1) 159
monocytes
  and the uPA receptor 27
morphine
  and cholecystokinin 65
motoneurones
  and 5-HT receptors 288, 444 (L), 445 (L)
  and metabotropic glutamate receptor antagonists 334
motor patterns
  and dynorphin A 422
  5-HT receptors in 288
mRNA detection
  in expression cloning 439
MT (muscarinic toxin) 1, 424
multidrug resistance (MDR) 86, 260, 445 (L)
multidrug therapy
  and AIDS 137 (L)
muscarinic acetylcholine receptors
  antisense 'knockout' studies of 251
  and Ca^{2+} influx 82
  and clozapine 267
  discrimination of coexpressed subtypes 117
  and mamba toxins 1, 424
  in smooth muscle 114, 407 (L)
muscle-derived relaxing factor (MDRF) 257
muscular dystrophy
  and calpain 416
mutational studies
  in *Chlamydomonas* 343
  of G protein action 250
mutagens
  as carcinogens 89
myocardium
  and calpain 416
  and ischaemic preconditioning 19, 304
myo-inositol
  and diabetes mellitus 294

N

Na^+
  and G-protein-coupled receptors 122
Na^+ channels 2, 458
NADPH
  and diabetes mellitus 294
NADPH–cytochrome P-450 reductase 248
naloxone 420
NECA 13 (L)
nemonapride 318
nerve growth factor (NGF)
  and inflammation 192
nerve injury
  and cholecystokinin 65
  and chronic pain 190
  and lipocortin-1 75
neurochemical systems
  effects of phenylglycines on 335
neurodegeneration
  in Alzheimer's disease 449

and calpain 416
neuroendocrine system
lipocortin-1 in 73
neurokinin A 190
neurokinin receptors 194
neuroleptics 264, 377
neuromuscular junction
and clostridial toxins 3
neuronal modulation
and airway hyperreactivity 466
by antidepressants 222
by 5-HT 290
by metabotropic glutamate receptor antagonists 334
neuropathic pain 193
neuropeptides
and inflammation 190
neuropeptide Y 153
neuropeptide Y receptors 154
neurotoxins 1, 147, 424
neurotransmitter receptors
in developing nervous system 351 (BR)
NF-AT (nuclear factor of activated T cells) 331
NF-κB (nuclear factor-κB) 239
NGF, *see* nerve growth factor
nicotinic acetylcholine receptors
and mamba toxins 1
structure of 185
(+) niguldipine 167
Nipkow-disc-based confocal microscopy 276
nitrates (organic)
biotransformation of 245
nitric oxide, *see* NO
NK1.1$^+$ cells (T cells) 325
NMDA receptors
and antiepileptic drugs 461
and anxiety 39
and chronic pain 193
and dynorphin A 422
and lipocortin-1
regulation in kindling 134
NO (nitric oxide)
in biotransformation of organic nitrates 245
in cardiac muscle 258
and diabetes mellitus 294
and headache 149
and hypoxia 50
and inflammation 191
and ischaemic preconditioning 21
and NSAIDS 406
in vascular smooth muscle 255
NO inhibitors 255
NO synthase
and headache 152
and inflammation 192
types of 255
nociception
and cholecystokinin 65
and chronic pain 190
and dynorphin A 421
in headache 149
non-receptor tyrosine kinases 61, 113
nonselective cation channels 431 (BR)
non-steroidal anti-inflammatory drugs (NSAIDS) 191, 405
noradrenaline
and anxiety
and depression 220
and locomotion 291
and neuropeptide Y 154
NSAIDS, *see* non-steroidal anti-inflammatory drugs
nuclear factor-κB (NF-κB) 239
nuclear magnetic resonance (NMR) spectroscopy
and peptide mimetic design 124

O

occupancy theory
for ligand–receptor interaction 140, 320 (L), 321 (L)
17β-oestradiol 85
oligodeoxynucleotides
in antisense technology 42, 251
and *in situ* hybridization 132
Ontario
pharmacology in 206
opiate withdrawal
and dynorphin A 422
opioids 65, 192, 420
optical isomers 335, 387
organic nitrates
biotransformation of 245
osmoregulation
and aldose reductase 293
oxygen
supply to tissue 48
oxymetazoline 167
oxytocin
concentration–response curves in uterus 181

P

P boxes (promoters of transcription) 331
P-glycoprotein 260, 445 (L)
p90^{rsk} protein 241
PACAP, *see* pituitary adenylate cyclase activating peptide
pain
central 196
and cholecystokinin 65
chronic, pharmacology of 190
and dynorphin A 421
and NO 149
panic disorders
animal models of 36
panning
in expression cloning 437
paralysis
and dynorphin A 420
parasympathetic nervous system
and muscarinic acetylcholine receptors 118
parasympatholytics 467
Parkinson's disease
and dopamine receptors 264
partial agonists
concentration–response curves for 140, 320 (L) (321 (L)
dopamine, and psychostimulant addiction 374
for metabotropic glutamate receptors 333
pathology, *see* anxiety, cerebrovascular disease, headache, pain, and renal disease
(*see also* named diseases)
Paton, William 15 (Obituary)
PD134308 357
PD142893 383
PDGF, *see* platelet-derived growth factor
pentylenetetrazol (PTZ) test 460
peptide fragments
of lipocortin-1 74
of PACAP 97
of prolactin 34
peptide mimetics
design of 124peptide YY 153
pergolide 376
periaqueductal grey
and panic disorders 36
peripheral nervous system
and neuropeptide Y 154
pH
and P-glycoprotein 261, 445 (L)
and signal transduction (*Chlamydomonas*) 347
pharmaceutical industry
in Canada 210
and pharmacologists 17
pharmacogenetics 309 (BR)
pharmacology
in Canada July
of chronic pain 190
dictionary 391 (BR)
as a discipline 17, 175, 176, 177, 202, 205, 211, 283, 399, 410 (L), 411 (L)
pharmacophoric groups
and peptide mimetic design 124
phenobarbitone
and non-genotoxic carcinogenesis 92, 322 (L), 323 (L)
phentolamine 167
phencyclidine (PCP) site (NMDA receptor complex) and dynorphin A 422
phenylglycine derivatives
as metabotropic glutamate receptor antagonists 333
phorbol esters 53
phorbol ester receptors 55
phosphatidic acid 58
phosphodiesterases 370, 467
phospholipase C 58
phospholipase D 57, 174 (L)
phosphorylation
and β-adrenoceptor action 370
and gene expression 239
and IL-4 signalling 330
of kainate receptors 185
by phorbol esters 54
tyrosine, and Ca^{2+} influx 282 (L)
photophobia (*Chlamydomonas*) 343
photoreceptor (*Chlamydomonas*) 343
phototaxis (*Chlamydomonas*) 343
physiologists (women) 31 (BR)
pindolol 225
pirenzepine 115, 425
pituitary adenylate cyclase activating peptide (PACAP) receptors 97
plaques, senile
and inflammatory proteins 447
plasminogen activator (urokinase-type)
and metastasis 25
plasminogen activator inhibitor type-1 (PAI-1) 25
Plasmodium vivax
and erythrocyte chemokine receptor 163
platelet aggregation 103, 417, 452
platelet-derived growth factor (PDGF) 59, 108
platelet factor 4
as angiosuppressor 35
polar allosteric pocket
of G-protein-coupled receptors 170
polyethylene glycol (PEG)
and liposomes 215
polymorphism
of D_4 dopamine receptor gene 317
polyphosphoinoside turnover
and Ca^{2+} influx 77
and caffeine 146
and M_3 muscarinic acetylcholine receptors 116
postsynaptic receptors
and antidepressants 225
potassium channels, see K^+ channels
prazosin 167
preclamol 376
pregnancy
NO production during 255
presynaptic depression
and metabotropic glutamate receptors 337
presynaptic receptors (brain) 433 (BR)
prolactin
as angiosuppressor 34
prostacyclin
and headache 151
and hypoxia 49
and ischaemic preconditioning 21
and protein kinase C 55
prostaglandins

and NO 258
and NSAIDS 191, 405
in platelet aggregation 103
proteases
and Alzheimer's disease 448
protease inhibitors 26, 34
protease nexin-1 27
protein kinase A
and β-adrenoceptor action 371
in cell signalling 243
and 5-HT receptors 451
and kainate-binding proteins 185
protein kinase C
and angiogenesis 34
and Ca^+ waves in cell migration 272
and ischaemic preconditioning 24
and phospholipase D 58
role in cellular activation 53
protein kinase C inhibitors 53
protein kinase G
and β-adrenoceptor action 371
plasma-membrane electrochemical potential ($\Delta\Psi$)
and P-glycoprotein 445 (L)
protein structure
of adenosine receptors 298, 311
of the aromatic hydrocarbon receptor 229
of calpain 412
of chemokine receptors 159
of dopamine receptors 264
of endothelin converting enzyme 1 313
of erabutoxin-a 1
of G protein-coupled receptors 170
of IL-4 and receptor complex 330
of kainate receptors 183
of muscarinic toxins 428
of neuropeptide Y 153
of P_2 purinoceptors 69, 311
of receptor classes 355
of rhodopsins 8
of uPA receptor 27
psychostimulant addition 374
pulmonary artery 47, 257
P_2 purinoceptors
for ADP 103
classification of 67, 280 (L)
expression cloning of 311

Q

Québec
pharmacology in 205
quinuclidinylbenzilate (QNB) 425

R

racemates 102 (L), 246, 335
raclopride 318
radiolabels
for molecular probes 132
Raf 241
RANTES (regulated on activation normal T-cell expressed and secreted) 159
Ras signalling pathway
and DNA methyltransferase 234
rauwolscine 119
razoxane
and angiosuppressor 35
receptors
autoradiography of 393 (BR)
characterization of and ligand design for 355
classification of 203, 355
coupling to phospholipase D 60
in developing nervous system 351 (BR)
expression cloning of 438
kinetics 29 (BR)
nomenclature 203
and peptide mimetics 127
presynaptic 433 (BR)
regulation, and *in situ* hybridization 131
(*see also* named receptors)
receptor–ligand interaction, see ligand–receptor interaction
Receptor Nomenclature and Drug Classification Committee (NC-IUPHAR) 203
reconstitution studies
of G protein action 250
regioselectivity
of biotransformation of organic nitrates 246
regulatory DNA elements 239
Rel proteins 243
renal disease
and endothelin 1 315
renzapride 452
research
fraud and misconduct in 308 (BR)
into G proteins 442
pharmacological 284, 399
principles in 198 (BR)
respiration
and 5-HT receptors 290
respiratory tract
pharmacology of 63 (BR)
(*see also* lung)
restenosis
and calpain 418
reverse transcriptase (of HIV-1)
and zidovudine resistance 137 (L)
rhythmic locomotion
and 5-HT receptors 288
risperidone 167, 266
RNA editing 183
RNA probes
for *in situ* hybridization 131
Ro318425 56
Ro462005 11
Rodbell, Martin (1994 Nobel prize) 442
RSI5385 120
ryanodine receptor 145, 271

S

Saccharomyces cerevisiae
P-glycoproteins in 261
sarafotoxin S6b 380
sarafotoxin S6c 9, 380
Saskatchewan
pharmacology in 209
SB203186 451
SB207710 451
SB209670 315
schizophrenia 264, 318
screening procedure
in expression cloning 439
SDZ205557 454
SDZ208911 376
SDZ208912 376
SDZENS163 116, 407 (L)
SDZPCO400 464
sec 6-4 (yeast mutant)
P-gycoprotein expression in 262
second messengers
for α_2-adrenoceptors 122
for β-adrenoceptors 370
for Ca^{2+} influx 79, 103
for endothelin receptors 380
history of research into 442
secretin 98
secretion
analysis by confocal microscopy 279
and Ca^{2+} waves 272
secretory granules
and platelet aggregation 103
secretory vesicles (yeast)
P-glycoproteins in 262
sedation
and neuropeptide Y 153
segmental monosynaptic reflex pathways
and 5-HT 291
seizures
drugs for 456
and dynorphins 422
and *in situ* hybridization 134
selective 5-HT (serotonin) reuptake inhibitors (SSRIs) 220
senile plaques
and inflammatory proteins 447
sensitization (receptor)
and antidepressants 224
sensory neurones
and chronic pain 190
and motor patterns 289
serum response element (SRE) 239
serum response factor (SRF) 240
sexual signalling (*Chlamydomonas*) 347
SH2 (Src homology region 2) domains 240, 330
shear stress
and NO release 256
shuttle vectors 437
SIE [c-Sis (platelet-derived growth factor)-inducible element] 239
signal cross-talk 243, 407 (L), 454
signal visualization
in *in situ* hybridization 133
signalling systems
affecting cell migration 26
analysis by antisense technology 250
for Ca^{2+} influx 77, 103, 271, 282 (L)
in *Chlamydomonas* 343
in control of gene expression 239
for DNA methyltransferase expression 234
and dose–response curves 178
for EGF 110
for G protein-coupled receptors 170
for IL-4 330
in ischaemic preconditioning 22
and mitogenesis 59
in platelet aggregation 104
role of protein kinase C 53
and tyrosine kinases 108
sinoatrial 5-HT receptors 453
c-Sis (platelet-derived growth factor)-inducible element (SIE) 239
SK&F104078 121
SK&F108566 126
SKF525A 247
smooth muscle
Ca^{2+}-release channels in 146
and hypoxia 50
muscarinic acetylcholine receptors in 114, 407 (L)
and tyrosine kinase pathways 108
(*see also* airway, arterial, cardiac and vascular smooth muscle)
SNAP-25 (synaptosome-associated protein 25) 2
sodium channels, *see* Na^+ channels
somatostatin receptors
antisense 'knockout' studies of 251
sorbinil 296
sorbitol 293
spasolysis 464
spectrin 412
sphingosine 59
spinal cord
and chronic pain 193
5-HT receptors in 288, 444 (L), 445 (L)
spinal cord injury
and calpain 416
and dynorphin A 421
spiperone 167, 266, 318
spleen
adenosine A_3 receptors in 301
cannabinoid receptors in 40
squamous lung carcinoma (murine)
drug delivery to by immunoliposomes 218
SR58894 397
SR59230 397
SRE (serum response element) 239
SRF (serum response factor) 240

SSRIs [selective 5-HT (serotonin) reuptake inhibitors] 220
ST271 61
Stat91 (signal transducer and activation of transcription 91) 239, 331
staurosporine 53
STE6 (ATP-binding cassette membrane transporter) (yeast) 260
sterically stabilized liposomes 215
stereoselective anaesthetics 387
stimulatory receptors
  and concentration–response curves 140, 321 (L)
  (*see also* AMPA, kainate, metabotropic glutamate and NMDA receptors)
stress
  and α_2-adrenoceptors 122
  and neuropeptide Y 158
  neuropharmacology of 36
stringency
  and *in situ* hybridization 133
stroke
  and 5-HT 452
structure–function relationships
  for adenosine A_3 receptors 302
  for the aromatic hydrocarbon receptor 230
  for endothelin receptors 313
  and the molecular lipophilicity potential 359
  for P-glycoproteins 260
subarachnoid haemorrhage
  and calpain 415
substance P 190
subunits (kainate receptors) 182
sulphisoxazoles 315
sulphonamides
  and non-genotoxic carcinogenesis 91
swimming
  and 5-HT receptors 288
  in response to light (*Chlamydomonas*) 343
sympathetic neurones
  and inflammation 192
sympathomimetics 467
symptomatic vascular headache 151
synaptic plasticity
  and metabotropic glutamate receptors 339
synaptic transmission
  and clostridial toxins 2
  and metabotropic glutamate receptors 337
synaptobrevin 2
synaptosomal membranes
  muscarinic acetylcholine receptors in 425
syntaxin 2

T

T cells
  and cyclosporin A 99
  helper, in allergy and asthma 324
  I_{crac} in 78
  and protein kinase C inhibitors 53
T_4
  and sulphonamides 92
T_H2 cells (helper T cells)
  in allergy and asthma 324
tachycardia
  and 5-HT 451
tachykinin receptors 194, 357
tachyphylaxis
  reversal with losartan 366
tamandron 87
tamoxifen 83
targeted drug delivery (liposomal) 215
tau pathology (Alzheimer's disease) 447
taurine
  and diabetes mellitus 294
teaching pharmacology 175, 211, 286, 399
template
  in peptide mimetic design 124
terguride 376
tetanus toxin 3
2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) 226
TGF-β, *see* transforming growth factor β
thapsigargin
  and Ca^{2+} influx 77
theophylline 300, 467
three-dimensional quantitative structure–activity relationships (3D QSAR) 469 (BR)
thrombospondin 103
thromboxane A_2 103
thrombus formation
  and 5-HT 452
thyroid gland
  and sulphonamides 92
tiagabine 462
ticlopidine 107
tissue expression
  of adenosine A_3 purinoceptors 300
  of adrenoceptor types 397
  of α_1-adrenoceptors 168
  of β_3-adrenoceptor 3
  of D_4 dopamine receptors 317
  of lipocortin-1 71
  of neuropeptide Y receptors 155
  of P_{2Y}-purinoceptors 69
  of protein kinase C 55
toad
  kainate-binding proteins in 186
tolerance
  ischaemic 19
  opiate, and dynorphin A 422
  to organic nitrates 248
tolrestat 296
toxicology
  studies *in vitro* 30 (BR)
toxins
  aromatic hydrocarbon receptor ligands as 228
  and inflammation 432 (BR)
  (*see also* neurotoxins)
training programmes (pharmacology) 17, 176, 177, 205, 211, 283, 399
transcription factors, *see* activator protein 1 and aromatic hydrocarbon receptor
transforming growth factor β (TGF-β) 25
transmembrane domains
  in G protein-coupled receptors 7
  in kainate receptors 183
  in P-glycoproteins 260
transport kinetics 29 (BR)
transport proteins
  and multidrug resistance 260
tricyclic antidepressant drugs 224
tumorigenesis 90, 235
tumour suppressors
  and DNA methylation patterns 236
tumours
  angiosuppressive therapy for 33
  and DNA methylation 235
  drug delivery to by liposomes 215
  and 5-HT 452
  and non-genotoxic carcinogenesis 89
  and tamoxifen 86
tyrosine kinase inhibitors 110, 282 (L)
tyrosine kinase receptors
  and carcinogenesis 91
  and cell signalling 240
  and phospholipase D 59
  and smooth muscle 108
tyrphostin 110

U

UK14304 119
universities (Canadian)
  pharmacology in 205, 211
uPA, *see* urokinase-type plasminogen activator
uPA receptor 27
urokinase-type plasminogen activator (uPA) 25
US28 (viral protein) 162

V

vagus nerve
  and airway hyperreactivity 465
vascular headache
  and NO 149
vascular endothelial growth factor 33
vascular smooth muscle
  and endothelin receptors 10, 313, 381
  and NO 255
  and organic nitrate biotransformation 245
  and phospholipase D 61
vascular tone 154, 256
vasculoprotection
  and endothelin 314
vasoactive intestinal polypeptide (VIP) receptors 97
vasoconstriction
  and endothelin receptors 9, 136 (L), 313, 381
  and hypoxia 47
  and neuropeptide Y 154
vasodilation
  and EGF 109
  and endothelin receptors 9, 313, 381
  and hypoxia 47
  and NO 255
  and organic nitrates 245
vasotocin 181
venom
  neurotoxins in 1, 147, 424
vertebrates
  kainate-binding proteins in 185
vigabatrin 456
VIP, *see* vasoactive intestinal polypeptide
viruses
  and asthma 328
  chemokine receptors in 162
  and tamoxifen 87
Wang, Zhen-Gang (Advisory Editorial Board) 12

W

WAY121509 295
WB4101 167
WIN55212-2 40
wind-up 194
withdrawal (drug abuse) 375
women
  in physiology 31 (BR)
work experience
  and education in pharmacology 401

X

X-ray diffraction
  and peptide mimetic design 124
xanthines 13 (L), 298
xenobiotics
  and inflammation 432 (BR)
xenobiotic-responsive elements (XREs) 227
Xenopus oocytes
  Ca^{2+} sparks in 271

Y

yeast
  P-glycoprotein in 261
yohimbine 119

Z

zamifenacin 116
Zbinden, Gerhard 16 (Obituary)
ZD6169 403
zenarestat
zidovudine 137 (L)
ZM172405 402
ZM226600 402
zopolrestat 297

Book Review Index

A

Adams, J. and Merluzzi, V. J., eds *The Search for Anti-Viral Drugs* 307

Audus, K. L. and Raub, T. J., *Biological Barriers to Protein Delivery* 64

B

Beynon, R. J., *Postgraduate Study in the Biological Sciences: A Researcher's Companion* 198

Bindman, L., Brading, A. and Tansey, T., ed, *Women Physiologists* 31

Burch, R. M., Kyle, D. J. and Stormann, T. M., *Molecular Biology and Pharmacology of Bradykinin Receptors* 94

C

Chung, K. F. and Barnes, P. J., eds, *Pharmacology of the Respiratory Tract: Lung Biology in Health and Disease, Volume 67* 63

D

Dunwiddie, T. V. and Lovinger, D. M., eds, *Presynaptic Receptors in the Mammalian Brain* 433

E

Escande, D. and Standen, N., eds, *K^+ Channels in Cardiovascular Medicine* 350

G

Gerald, M. C., *The Poisonous Pen of Agatha Christie* 307

Giesen-Crouse, E., ed., *Peripheral Benzodiazepine Receptors* 63

Grinspoon, L. and Bakalar, J. B., *Marihuana: The Forbidden Medicine* 94

H

Hallström, C., ed., *Benzodiazepine Dependence* 198

K

Kozikowski, A. P., ed., *Drug Design for Neuroscience* 93

Kubinyi, H., ed., *3D QSAR in Drug Design* 469

L

Laurence, D. R. and Carpenter, J. R., *A Dictionary of Pharmacology and Clinical Drug Evaluation* 391

Lock, S. and Wells, F., eds, *Fraud and Misconduct in Medical Research* 308

M

Matthews, J. C., *Fundamentals of Receptor, Enzyme and Transport Kinetics* 29

P

Page, C., ed., *Handbook of Immunopharmacology* 393

Price Evans, D. A., *Genetic Factors in Drug Therapy* 309

S

Sahgal, A., ed., *Behavioural Neuroscience: A Practical Approach, Volume II* 199

Schook, L. B. and Laskin, D. L., eds, *Xenobiotics and Inflammation* 432

Siemen, D. and Hescheler, J., eds, *Nonselective Cation Channels: Pharmacology, Physiology and Biophysics* 431

Sitkovsky, M. V. and Henkart, P. A., eds, *Cytotoxic Cells: Recognition, Effector Function, Generation and Methods* 165

Spooner, P. M. and Brown, A. M., eds, *Ion Channels in the Cardiovascular System: Function and Dysfunction* 470

T

Taylor, J. B. and Kennewell, P. D., *Modern Medicinal Chemistry* 350

Thomson, A. W. and Starzl, T. E., eds, *Immunosuppressive Drugs: Developments in Anti-rejection Therapy* 469

Tyson, C. A. and Frazier, J. M. eds, In Vitro *Biological Systems* 30

V

van Haaren, F., ed., *Methods in Behavioral Pharmacology: Techniques in the Behavioral and Neural Sciences, Volume 10* 200

Vinter, J. G. and Gardner, M., eds, *Molecular Modelling and Drug Design* 395

W

Watson, S. and Arkinstall, S., *The G-Protein Linked Receptor FactsBook* 431

Wharton, J. and Polak, J. M., eds, *Receptor Autoradiography Principles and Practice* 392

Z

Zagon, I. S. and McLaughlin, P. J., eds, *Receptors in the Developing Nervous System (Volume 1, Growth Factors and Hormones; Volume 2, Neurotransmitters)* 351

Back Issues of Elsevier Trends Journals

Back issues from 1993 and 1994 are available to our customers at the following rates. Please state which issue(s) and quantity you require, including the volume and number (or year and month).

Issues(s): _____

_____

_____

Please tick how many copies you would like below. Back issues are available in bulk at discounted rates – institutions/libraries must pay institutional rates.

Individual Rates

- ❑ Single copy £16.00/$25.00 each
- ❑ Five copies £68.00/$106.00 (includes 15% discount)
- ❑ Ten copies £120.00/$187.00 (includes 25% discount)

Institutional Rates

- ❑ Single copy £33.00/$52.00 each
- ❑ Five copies £140.00/$218.00 (includes 15% discount)
- ❑ Ten copies £248.00/$387.00 (includes 25% discount)

*Hardbound compendia of previous volumes are available to institutional subscribers. Please ask for further details.

PAYMENT METHOD:

- ❑ Personal cheque, Eurocheque, or money order made payable to **Elsevier**
- ❑ Credit card
  - ❑ Visa ❑ Mastercard ❑ American Express

Card no: _____

Expiry date: _____

Name on card: _____ Signature: _____

Total Payment sent: _____

Name: _____

Position: _____

Address: _____

_____

_____

Zip/Post Code: _____

Country: _____

Telephone: _____ Fax: _____

Please send this order with payment to:

Elsevier Trends Journals, Oxford Fulfilment Centre, PO Box 800, Kidlington, Oxford OX5 1DX.
Tel: +44 (1865) 843300; Fax: +44 (1865) 843940

Elsevier Trends Journals, 660 White Plains Road, Tarrytown, NY 10591–5153, USA.
Tel: +1 (914) 524 9200; Fax: +1 (914) 333 2444. E-mail: a.fricker@elsevier.co.uk

Rapid access

...to the cutting edge of science



Titles in the Trends series:

Immunology Today
Parasitology Today
Trends in Biochemical Sciences
Trends in Biotechnology
Trends in Cell Biology
Trends in Ecology & Evolution
Trends in Food Science & Technology
Trends in Genetics
Trends in Microbiology
Trends in Neurosciences
Trends in Pharmacological Sciences
Trends in Polymer Science

1995 order form

☐ **YES I must subscribe to** _____ **now!**

☐ Personal £72.00+VAT*/$115.00
☐ Student (50% discount) £36.00+VAT*/$58.00 (please send proof of student status)
12 monthly issues beginning _____ (enter month in 1995)

☐ Institutional/Library £345.00+VAT*/$514.00
(12 monthly issues Jan-Dec, plus hard-bound annual compendium)

☐ URGENT! Send me a FREE sample copy of

_____

PAYMENT DETAILS

☐ Cheque made payable to 'ELSEVIER'
☐ Credit card ☐ Visa ☐ Mastercard ☐ Am. Express
Card No. _____
Exp Date _____ Total Payment _____

Signature _____

ADDRESS DETAILS

Name _____
Position _____
Address _____
_____
Zip/Post Code _____ Country _____
Tel _____
Fax _____

☐ Please do not send me information from other organisations

***EU Non-UK Customers** Non-registered customers must pay VAT. Please add VAT (at your country's rate) to the price. VAT registered customers: please provide VAT registration no:

_____

Photocopy this ad and return this form to
UK Elsevier Trends Journals, Oxford Fulfilment Centre, PO Box 800, Kidlington, Oxford, UK OX5 1DX.
USA Elsevier Trends Journals, 660 White Plains Road, Tarrytown, NY 10591-5153, USA

TH5A03

For more information:

USA enquiries
Tel: +1 (914) 524 9200 Fax:+1 (914) 333 2444

Europe/ROW enquiries
Tel: +44 (1865) 843300 Fax: +44 (1865) 843940

Australia enquiries
Tel: +61 (2) 958 4429 Fax: +61 (2) 967 2126

Japan enquiries
Tel: +81 (3) 3836 0810 Fax: +81 (3) 3839 4344

E-mail enquiries
subscribe.trends@elsevier.co.uk

ELSEVIER TRENDS JOURNALS

Elsevier Trends Journals
The science of information